The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe

Ruiz-Casas, Leonardo; Evans, Jonathan; Rose, Alison; Pedra, Gabriel; Lobo, Alan; Finnegan, Alan; Hayee, Bu; Peyrin-Biroulet, L; Sturm, Andreas; Burisch, Johan; Terry, Helen; Avendano, Luisa; Tucknott, Seb; Fiorino, Gionata; Limdi, Jimmy K.

doi:10.1186/s12876-021-02028-5

Cited by 10 publications

(8 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, at 2015 values, a higher cost per patient/year in CD (€3542) compared to UC was also observed in this study (€2088) [ 69 ]. Another recent pan-European study raised the mean annual direct medical, direct non-medical and indirect costs for UC in Spain up to €4551, €1321 and €3061 respectively, resulting in a mean annual total cost of €8934 [ 70 ]. This cost was the highest among the 10 participating countries of the study, with an overall mean annual total cost of €7854, all in 2019 prices [ 70 ].…”

Section: Discussionmentioning

confidence: 99%

Epidemiological, Clinical, Patient-Reported and Economic Burden of Inflammatory Bowel Disease (Ulcerative colitis and Crohn’s disease) in Spain: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Introduction This study describes the epidemiological, clinical, patient-reported and economic burden of inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), in Spain. Methods A systematic review was performed of observational studies reporting the epidemiological, clinical, patient-reported and economic burden of IBD in the Spanish population, from 2011 to 2021. Original articles and conference abstracts published in English or Spanish were eligible. Results A total of 45 publications were included in the review. The incidence of IBD in adults ranged from 9.6 to 44.3 per 100,000 inhabitants (4.6 to 18.5 for CD and 3.4 to 26.5 for UC). The incidence increased between 1.5- and twofold from 2000 to 2016 (regionally). Up to 6.0% (CD) and 3.0% (UC) IBD-associated mortality was reported. Disease onset predominantly occurs between 30 and 40 years (more delayed for UC than CD). Most frequently reported gastrointestinal manifestations are rectal bleeding in UC and weight loss in CD. Extraintestinal manifestations (EIM) have been described in up to 47.4% of patients with CD and 48.1% of patients with UC. Psychiatric comorbidities were frequently reported in both CD and UC (depression up to 20% and anxiety up to 11%). Reduced health-related quality of life (HRQoL) compared to the general population was reported. Significant symptomatology was associated with high levels of anxiety, depression, stress and lower HRQoL. Main healthcare resources reported were emergency department visits (24.0%), hospitalization (14.7%), surgery (up to 11%) and use of biologics (up to 60%), especially in CD. Direct and indirect annual costs per patient with UC were €1754.1 and €399.3, respectively. Conclusion Patients with CD and UC present a high disease burden which negatively impacts their HRQoL, leading to elevated use of resources. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-023-02473-6.

show abstract

Section: Discussionmentioning

confidence: 99%

Epidemiological, Clinical, Patient-Reported and Economic Burden of Inflammatory Bowel Disease (Ulcerative colitis and Crohn’s disease) in Spain: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…[17][18][19][20][21][22] A further study focused on the costs and health-related quality of life (HRQoL) impacts of active UC and showed that there were high costs of care (direct and indirect) and adverse effects on HRQOL. 35 Combined with the results from our modelling, it would suggest that the optimised treatment pathway is highly likely to be cost-saving and therefore likely to be dominant over the standard treatment pathway. This is a potential area for further investigation and future extension of this current model.…”

Section: Discussionmentioning

confidence: 62%

“…In all cases, these analyses showed that the optimised therapy was the dominant treatment option (lower costs and higher-quality-adjusted life-years) 17–22. A further study focused on the costs and health-related quality of life (HRQoL) impacts of active UC and showed that there were high costs of care (direct and indirect) and adverse effects on HRQOL 35. Combined with the results from our modelling, it would suggest that the optimised treatment pathway is highly likely to be cost-saving and therefore likely to be dominant over the standard treatment pathway.…”

Section: Discussionmentioning

confidence: 97%

Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis

Louis

Paridaens

Awadhi

et al. 2022

BMJ Open Gastroenterol

View full text Add to dashboard Cite

Objectives5-aminosalicylate (mesalazine; 5-ASA) is an established first-line treatment for mild-to-moderate ulcerative colitis (UC). This study aimed to model the benefits of optimising 5-ASA therapy.MethodsA decision tree model followed 10 000 newly diagnosed patients with mild-to-moderately active UC through induction and 1 year of maintenance treatment. Optimised treatment (maximising dose of 5-ASA and use of combined oral and rectal therapy before treatment escalation) was compared with standard treatment (standard doses of 5-ASA without optimisation). Modelled data were derived from published meta-analyses. The primary outcomes were patient numbers achieving and maintaining remission, with an analysis of treatment costs for each strategy conducted as a secondary outcome (using UK reference costs).ResultsDuring induction, there was a 39% increase in patients achieving remission through the optimised pathway without requiring systemic steroids and/or biologics (6565 vs 4725 for standard). Potential steroidal/biological adverse events avoided included: seven venous thromboembolisms and eight serious infections. Out of the 6565 patients entering maintenance following successful induction on 5-ASA, there was a 21% reduction in relapses when optimised (1830 vs 2311 for standard). This translated into 297 patients avoiding further systemic steroids and 214 biologics. Optimisation led to an average net saving of £272 per patient entering the model for the induction and maintenance of remission over 1 year.ConclusionModelling suggests that optimising 5-ASA therapy (both the inclusion of rectal 5-ASA into a combined oral and rectal regimen and maximisation of 5-ASA dose) has clinical and cost benefits that supports wider adoption in clinical practice.

show abstract

“…After publication of this article [ 1 ], the authors reported that the author name “Avedano” was incorrectly written as “Avendano”.…”

Section: Correction To: Bmc Gastroenterology (2021) 21:456 101186/s12876-021-02028-5mentioning

confidence: 99%

Correction to: The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe

Ruiz-Casas¹,

Evans²,

Rose³

et al. 2021

BMC Gastroenterol

Self Cite

View full text Add to dashboard Cite

The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe

Cited by 10 publications

References 37 publications

Epidemiological, Clinical, Patient-Reported and Economic Burden of Inflammatory Bowel Disease (Ulcerative colitis and Crohn’s disease) in Spain: A Systematic Review

Epidemiological, Clinical, Patient-Reported and Economic Burden of Inflammatory Bowel Disease (Ulcerative colitis and Crohn’s disease) in Spain: A Systematic Review

Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis

Correction to: The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe

Contact Info

Product

Resources

About